The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
November 23rd 2024
With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.
November 18th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Women with Acute Ischemic Stroke Less Likely to Receive Optimal Stroke Care
July 18th 2023An analysis of patient data from the greater Houston area suggests women were less likely to be routed to a comprehensive stroke center than their male counterparts, despite a greater symptom severity and comparable distance to the centers.
Study Finds Prescribing Fruits and Vegetables Could Reduce Future Healthcare Spending by $40 Billion
July 14th 2023A microsimulation model leveraging data from NHANES suggests monthly prescriptions of fruits and vegetables to people with diabetes and food insecurity could prevent nearly 300,000 cardiovascular disease events over a 25-year period.
Study Identifies Potential Link Between Gut Microbiome and Atherosclerosis
July 12th 2023Using data from more than 8500 patients from a bioimaging study, investigators took a deep dive into potential associations between gut microbiome and subclinical atherosclerosis in adults without a history of cardiovascular disease
Expanded CGM Access Could Usher in New Era of Diabetes Management
July 10th 2023Expansions in access by the Centers of Medicare and Medicaid Services could bring the latest advances in continuous glucose monitoring into the hands of millions with diabetes, which could provide significant, population-level impact and bring the field a step closer to equitable diabetes management.
Diabetic Microvascular Disease Associated with Left Ventricular Hypertrophy in T2D
July 2nd 2023After adjusting for potential confounding factors, patients with microvascular diseases, particularly diabetic retinopathy, and diabetic kidney disease, were found to have a greater possibility of left ventricular hypertrophy.
Study Suggests Bempedoic Acid Could Find Role in Primary Prevention
June 24th 2023An analysis of a primary prevention subgroup within the CLEAR Outcomes trial presented at ADA 2023 suggests use of bempedoic acid was associated with a 30% relative risk reduction for MACE among this patient population.
SGLT2 Inhibitors Benefit CV Outcomes Across Heart Failure, T2D, CKD Populations
June 21st 2023A meta-analysis of 13 trials suggests SGLT2 inhibitors reduced heart failure events and cardiovascular death across these patient populations, with consistent effects in patients with varying disease combinations.
FDA Approves Colchicine Tablets for Reducing Cardiovascular Risk
June 20th 2023Announced by AGEPHA Pharma US on June 20, 2023, the US FDA approval of colchicine 0.5 mg tablets (Lodoco) for reducing cardiovascular event risk marks the first approval in agency history for an anti-inflammatory atheroprotective cardiovascular treatment.
Cardiology Case Report: Near Syncope
June 19th 2023This cardiology case report from Brady Pregerson, MD, features man in his late-60s presenting to urgent care with 3 days of upper respiratory infection symptoms and one episode of near syncope. Check out the ECG and see if you can determine the correct diagnosis!
FDA Approves Updated Label for Mavacamten in Obstructive Hypertrophic Cardiomyopathy
June 16th 2023On June 15, 2023, Bristol Myers Squibb announced the FDA approved an updated label for mavacamten (Camzyos) to reflect the agent's ability to reduce the need or eligibility for septal reduction therapy in patients with obstructive HCM based on VALOR-HCM.
Combination Obicetrapib plus Ezetimibe Shows Promise for Dyslipidemia in Phase 2 Trial
June 14th 2023New data from the phase 2 ROSE2 trial is providing insight into the safety and tolerability, as well as LDL-lowering effects, of obicetrapib as an adjunct to high-intensity statin therapy as a monotherapy and in combination with ezetimibe.
SGLT2 Inhibitor Prescription Rates Lag Behind in HFrEF, with Stephen Greene, MD
June 13th 2023Stephen Greene, MD, discusses the results of a recent GWTG-HF registry analysis, which concluded just 1 in 5 hospitalized patients with HFrEF were discharged with an SGLT2 inhibitor prescription and less than 10% were receiving all 4 classes of guideline-directed medical therapy.